Payment overview · 2025
General Payments
$666.37
30 reported records · 8 companies
Healthcare provider profile · identity verified
Andrew Rego, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · EAST PROVIDENCE, RI · NPI 1649644477
Verified facts
What the public records show
CMS Open Payments records show Andrew Rego, PAC received $666.37 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $215.46 | 32.3% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.77 | 18.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $103.80 | 15.6% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $94.98 | 14.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.83 | 6.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.38 | 6.4% | 2 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $32.43 | 4.9% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $14.72 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $666.37 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $127.43 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.56 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.56 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $94.98 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.68 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.78 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.38 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.38 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $32.43 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 104 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 151 |
| Lisinopril | Lisinopril | 429 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 84 |
| Omeprazole | Omeprazole | 281 | 88 |
| Metformin Hcl | Metformin Hcl | 257 | 72 |
| Losartan Potassium | Losartan Potassium | 170 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 40 |
| Allopurinol | Allopurinol | 126 | 33 |
| Simvastatin | Simvastatin | 120 | 34 |
| Gabapentin | Gabapentin | 119 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 26 |
| Ezetimibe | Ezetimibe | 115 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 22 |
| Trazodone Hcl | Trazodone Hcl | 105 | 22 |
| Eliquis | Apixaban | 104 | 14 |
| Jardiance | Empagliflozin | 104 | 27 |
| Sertraline Hcl | Sertraline Hcl | 101 | 32 |
| Alprazolam | Alprazolam | 98 | 20 |
| Furosemide | Furosemide | 90 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 20 |
| Metformin Hcl Er | Metformin Hcl | 82 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 23 |
| Alendronate Sodium | Alendronate Sodium | 79 | 23 |
| Montelukast Sodium | Montelukast Sodium | 79 | 23 |
| Valsartan | Valsartan | 72 | 16 |
| Glimepiride | Glimepiride | 67 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 64 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 18 |
| Chlorthalidone | Chlorthalidone | 53 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Ozempic | Semaglutide | 53 | suppressed |
| Glipizide | Glipizide | 49 | 14 |
| Naproxen | Naproxen | 46 | 17 |
| Azithromycin | Azithromycin | 44 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Carvedilol | Carvedilol | 39 | 12 |
| Famotidine | Famotidine | 39 | 12 |
| Irbesartan | Irbesartan | 39 | 11 |
| Farxiga | Dapagliflozin Propanediol | 38 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 14 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 14 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Clonazepam | Clonazepam | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $666.37 · 30 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, COMIRNATY, CREON, ELIQUIS, Exablate, FARXIGA, FREESTYLE LIBRE 3, Fibroscan, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error